SharkNinja Inc. Ordinary Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? SharkNinja Inc. Ordinary Shares trades at $184.66 (market cap $26.04B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.9× SharkNinja Inc. Ordinary Shares's market cap, and SharkNinja Inc. Ordinary Shares is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SharkNinja Inc. Ordinary Shares for 1 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SN | VRTX | |
|---|---|---|
Market Cap | $26.04B | $127.55B |
Volume | 994,345 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $192.86 | $557.96 |
52-Week Low | $84.57 | $407.37 |
Typical Hold Time | 1 Days | 120 Days |
Enterprise Value | $26.18B | $121.68B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SharkNinja designs and sells small household appliances under the Shark and Ninja brands. Its products include cleaning appliances, kitchen and beverage appliances, food preparation products, and beauty and home-environment devices.
Read more on SN →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →